Beirut
Beirut
Beirut, Lebanon81 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Roll-over Study to Allow Continued Access to Ribociclib | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 4 | 2026-10-09 | NCT05161195 | |
| Impact of Pharmacotherapy Optimization in Polymedicated Lebanese Older Adults in Primary Health Care Centers | Clinical Outcomes; Health Outcomes; Intrinsic Capacity; Older Adults (65 Years and Older); Pharmacotherapy Optimization; Polypharmacy (People Under Treatment With 5 or More Drugs); Primary Health Care; Quality of Life (QOL); Social Determinants of Health (SDOH) | Not yet recruiting | Not applicable | 2026-10-08 | NCT07866677 | |
| Long Term Extension Study in Patients With Primary Hyperoxaluria | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hyperoxaluria, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, kidney disorder, metabolic disease, primary hyperoxaluria, primary hyperoxaluria type 1, primary hyperoxaluria type 2, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT04042402 | |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholangitis, Sclerosing, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Abnormalities, Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary atresia, biliary tract disorder, cholangitis, skin disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06553768 | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05296798 | |
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT05134441 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770779 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770753 | |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT03466411 | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04557059 | |
| A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Recruiting | Phase 2 | 2026-09-18 | NCT06198712 | |
| Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, homozygous familial hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 3 | 2026-09-18 | NCT05682378 | |
| A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Phase 3 | 2026-09-18 | NCT05135559 | |
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | neoplasm | Active, not recruiting | Phase 4 | 2026-09-17 | NCT02584933 | |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Sickle Cell Trait, Vaso-Occlusive Crises, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 3 | 2026-09-14 | NCT03814746 | |
| An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiovascular disorder, congenital heart disease, heart disorder, heart septal defect, ventricular septal defect | Recruiting | Not stated | 2026-09-08 | NCT06823635 | |
| Electromyographic Effects of Postural Correction Exercises in Individuals With Forward Head Posture | Forward Head Posture | Recruiting | Not applicable | 2026-08-21 | NCT07780396 | |
| CINC424A2X01B Rollover Protocol | Bronchiolitis Obliterans, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, acquired polycythemia vera, acute myeloid leukemia, anemia, bone marrow disorder, bone marrow neoplasm, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, familial hemolytic anemia, graft versus host disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemolytic anemia, hereditary disease, immune system disorder, inherited hemoglobinopathy, leukemia, lung disorder, myeloid leukemia, neoplasm, obstructive lung disease, primary myelofibrosis, respiratory system disorder, thalassemia | Active, not recruiting | Phase 4 | 2026-08-20 | NCT02386800 | |
| Prospective Global Registry for the Study of Chronic Total Occlusion Intervention | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-08-19 | NCT02061436 | |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Active, not recruiting | Phase 3 | 2026-08-18 | NCT05147220 | |
| BPH Global Registry | Genital Diseases, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Recruiting | Not stated | 2026-08-13 | NCT05543200 | |
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-13 | NCT04603807 | |
| Puff Topography and Sensory Effects Across IQOS Device Generations | Chemically-Induced Disorders, nicotine dependence, psychiatric disorder, substance-related disorder | Recruiting | Not applicable | 2026-07-30 | NCT07712887 | |
| The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Active, not recruiting | Not stated | 2026-07-23 | NCT05847751 | |
| A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03523858 |